Brind.
  1. BBOT is conducting preclinical studies on several drug candidates, including BBO-10203, BBO-8520, and BBO-11818, targeting pathways like KRAS and PI3Kα.

BBO-8520, a drug candidate from BridgeBio Oncology Therapeutics, demonstrated a high response rate when combined with pembrolizumab. The compound functions as a KRASG12C inhibitor.

1 report, 1 independent Updated Sep 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BBO-8520, a drug candidate from BridgeBio Oncology Therapeutics, demonstrated a high response rate when combined with pembrolizumab. The compound functions as a KRASG12C inhibitor.

Keep exploring

Part of

BBOT is conducting preclinical studies on several drug candidates, including BBO-10203, BBO-8520, and BBO-11818, targeting pathways like KRAS and PI3Kα. All 1 developments

Coverage

Newest first; wire copies grouped